According to people close to the matter, Mylan has approached Actavis about a possible takeover, although a formal bid hasn't been submitted, Bloomberg reported Wednesday.
Last week, reports suggested that Watson was close to a deal to acquire Actavis and sources noted Wednesday that Watson is nearing an agreement under which it could pay approximately 4.5 billion euros ($6 billion) for the drugmaker. The people said that while a deal could be announced next week, it is more likely to come later in April. Spokespeople for all three companies declined to comment on the sales process.
The sources suggested that the complexity of Actavis’ businesses has been holding back other companies from making competing bids. However, the people indicated that the owners of Actavis are not expected to agree to an offer valued at less than 4 billion euros ($5.3 billion).
To read more Top Story articles, click here.